Editas Medicine (EDIT) Receivables - Net (2016 - 2025)
Editas Medicine (EDIT) has disclosed Receivables - Net for 11 consecutive years, with $8.1 million as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Net rose 6352.38% to $8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.1 million, a 6352.38% increase, with the full-year FY2024 number at $16.3 million, up 59.67% from a year prior.
- Receivables - Net was $8.1 million for Q3 2025 at Editas Medicine, up from $588000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $16.3 million in Q4 2024 to a low of $120000.0 in Q3 2022.
- A 5-year average of $2.6 million and a median of $588000.0 in 2025 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: plummeted 95.59% in 2021, then surged 6352.38% in 2025.
- Editas Medicine's Receivables - Net stood at $267000.0 in 2021, then skyrocketed by 1826.97% to $5.1 million in 2022, then surged by 98.0% to $10.2 million in 2023, then soared by 59.67% to $16.3 million in 2024, then tumbled by 50.02% to $8.1 million in 2025.
- Per Business Quant, the three most recent readings for EDIT's Receivables - Net are $8.1 million (Q3 2025), $588000.0 (Q2 2025), and $510000.0 (Q1 2025).